mobile nav toggler

investors

Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. Our mission is to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases.

DOWNLOAD THE LATEST PRESENTATION

recent releases
Apr 9, 2019

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has dosed the first...

Apr 2, 2019

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Douglas...

Mar 28, 2019

Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Jeffrey...

View All Releases >

current stock price
NASDAQPRVB
NASDAQPRVB

investor relations contact

For more information contact Joshua Drumm, Ph.D., Tiberend Strategic Advisors, Inc.
212.375.2664 

email Joshua

Sign Up For Email Alerts